scispace - formally typeset
Open AccessJournal ArticleDOI

Efficacy and safety of turmeric and curcumin in lowering blood lipid levels in patients with cardiovascular risk factors: a meta-analysis of randomized controlled trials.

Reads0
Chats0
TLDR
Turmeric and curcumin may protect patients at risk of CVD through improving serum lipid levels and may be used as a well-tolerated dietary adjunct to conventional drugs.
Abstract
Dyslipidemia is an important and common cardiovascular risk factor in the general population. The lipid-lowering effects of turmeric and curcumin are unconfirmed. We performed a meta-analysis to assess the efficacy and safety of turmeric and curcumin in lowering blood lipids in patients at risk of cardiovascular disease (CVD). A comprehensive literature search was conducted on PubMed, Embase, Ovid, Medline and Cochrane Library databases to identify randomized controlled trials (published as of November 2016) that assessed the effect of turmeric and curcumin on blood lipid levels including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Pooled standardized mean difference (SMD) with 95% confidence interval (CI) was used to assess the effect. The analysis included 7 eligible studies (649 patients). Turmeric and curcumin significantly reduced serum LDL-C (SMD = −0.340, 95% confidence interval [CI]: −0.530 to −0.150, P < 0.0001) and TG (SMD = −0.214, 95% CI: −0.369 to −0.059, P = 0.007) levels as compared to those in the control group. These may be effective in lowering serum TC levels in patients with metabolic syndrome (MetS, SMD = −0.934, 95% CI: −1.289 to −0.579, P < 0.0001), and turmeric extract could possibly have a greater effect on reducing serum TC levels (SMD = −0.584, 95% CI: −0.980 to −0.188, P = 0.004); however, the efficacy is yet to be confirmed. Serum HDL-C levels were not obviously improved. Turmeric and curcumin appeared safe, and no serious adverse events were reported in any of the included studies. Turmeric and curcumin may protect patients at risk of CVD through improving serum lipid levels. Curcumin may be used as a well-tolerated dietary adjunct to conventional drugs. Further research is required to resolve uncertainties related to dosage form, dose and medication frequency of curcumin.

read more

Content maybe subject to copyright    Report

Citations
More filters
Journal ArticleDOI

Targeting Foam Cell Formation in Atherosclerosis: Therapeutic Potential of Natural Products.

TL;DR: This review summarizes recent findings on the balanced effects of three major interrelated biologic processes, including lipid uptake, cholesterol esterification, and cholesterol efflux on foam cell formation and the development of foam cell-targeted therapeutic strategies.
Journal ArticleDOI

Nano-curcumin improves glucose indices, lipids, inflammation, and Nesfatin in overweight and obese patients with non-alcoholic fatty liver disease (NAFLD): a double-blind randomized placebo-controlled clinical trial

TL;DR: NC supplementation in overweight/obese NAFLD patients improved glucose indices, lipids, inflammation, WC, nesfatin, liver transaminases, and fatty liver degree, and the proposed mechanism for amelioratingNAFLD with NC was approved by the increased serum nesFatin and likely consequent improvements in inflammation,lipids, and glucose profile.
Journal ArticleDOI

ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.

TL;DR: An updated review of the expression, regulation, genetics, functions of ACLY in lipid metabolism and atherosclerosis, and the therapeutic potential of ACLy inhibitors (such as bempedoic acid, SB-204990, and other naturally-occuring inhibitors) to treat atherosclerotic cardiovascular diseases are provided.
Journal ArticleDOI

Curcumin Activates the Nrf2 Pathway and Induces Cellular Protection Against Oxidative Injury

TL;DR: It is demonstrated curcumin affects the Nrf2 signaling pathway to exert its therapeutic and biological activities and is safe and well-tolerated at high concentrations without making toxicity.
Journal ArticleDOI

Potential of Curcumin in Skin Disorders

TL;DR: The results suggest that curcumin may represent a low-cost, well-tolerated, effective agent in the treatment of skin diseases, and bypass of limitations of its in vivo use (low oral bioavailability, metabolism) is essential in order to conduct larger clinical trials that could confirm these observations.
References
More filters
Journal ArticleDOI

Estimating the mean and variance from the median, range, and the size of a sample.

TL;DR: Two simple formulas are found that estimate the mean using the values of the median, low and high end of the range, and n (the sample size) and these hope to help meta-analysts use clinical trials in their analysis even when not all of the information is available and/or reported.
Journal ArticleDOI

Bioavailability of curcumin: problems and promises.

TL;DR: Enhanced bioavailability of curcumin in the near future is likely to bring this promising natural product to the forefront of therapeutic agents for treatment of human disease.
Related Papers (5)